Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE®) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia

NCT00560794 is registered in ClinicalTrials.gov with Amgen Research (Munich) GmbH as lead sponsor.

NCT NCT00560794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00560794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE®) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia
Lead sponsor
Amgen Research (Munich) GmbH
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
November 30, 2014
Enrollment
21 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia